Supplementary Table S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid TumorsSolange Peters,Eric Angevin,Teresa Alonso-Gordoa,Kristoffer Rohrberg,Ignacio Melero,Begoña Mellado, Jose-Luis Perez-Gracia,Josep Tabernero, Celine Adessi,Christophe Boetsch,Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro,Valeria Nicolini,Stefan Evers,Christian Klein, Barbara Leutgeb, Pavel Pisa,Eva Rossmann, José Saro,Pablo Umana,Jehad Charo,Volker Teichgräber,Neeltje Steeghscrossref（2024）引用 0|浏览0暂无评分摘要Supplementary Table S1. Baseline demographic and clinical characteristics (safety population).更多查看译文AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
